Physical Fitness and Frailty in Males after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Long-Term Follow-Up Study

Cancers (Basel). 2022 Jul 7;14(14):3310. doi: 10.3390/cancers14143310.

Abstract

Purpose and methods: To analyze physical fitness, physical activity and the prevalence of frailty in male long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation (HSCT). We performed a Nordic two-center study of 98 male survivors (mean age 28.7 years, range 18.5-47.0) treated with pediatric allogeneic hematopoietic stem cell transplantation (HSCT) 1980-2010 in denmark or finland. physical fitness was evaluated by the dominant hand grip-strength, timed up-and-go, sit-to-stand, gait speed and two-minute walk tests.

Results: Survivors presented significantly lower muscle strength and muscle endurance in the dominant hand-grip strength (median Z-score -0.7, range -4.3-3.9) and sit-to-stand tests (median Z-score -1.5, range -3.5-2.5) compared to age and sex matched normative values of the tests. However, mobility and gait speed were not affected on a group level. The prevalence of frailty (pre-frail 20% or frail 10%) was high among the survivors. In multiple regression analysis, chronic graft-versus-host disease, shorter stature, higher body fat mass and hazardous drinking predicted prefrail/frail status. Common cardiovascular risk factors, such as increased levels of serum triglycerides, higher resting heart rate and diastolic blood pressure, were associated with lower physical fitness.

Conclusion: Low muscle strength and a high incidence of frailty were observed in survivors of pediatric HSCT. There is a predominant risk of cardiovascular and metabolic diseases in the long-term.

Keywords: GvHD; aging; frailty; late effects; pediatric hematopoietic stem cell transplantation; physical fitness.

Grants and funding

This research was funded by grants from the Finnish Cancer Society, the Finnish Foundation of Paediatric Research, Helsinki University Research Foundation (Finland), the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Birgitta and Carl–Axel Rydbeck’s Research Grant for Paediatric Research (Sweden), the Danish Childhood Cancer Foundation, Rigshospitalet’s Research Foundation (Denmark), the Danish Cancer Society, the Danish Cancer Research Foundation, Dagmar Marshall’s Fund (Denmark) and the Hartmann Brothers’ Fund (Denmark). Open access funding provided by University of Helsinki.